

PRODUCT INFORMATION



Elacridar

Item No. 18128

CAS Registry No.: 143664-11-3
Formal Name: N-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-4-acridinecarboxamide

Synonyms: GF120918, GG918, GW0918

MF: C₃₄H₃₃N₃O₅

FW: 563.6


Purity: ≥98%

UV/Vis.: λ_{max}: 258, 406 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Elacridar is supplied as a crystalline solid. A stock solution may be made by dissolving the elacridar in the solvent of choice, which should be purged with an inert gas. Elacridar is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of elacridar in these solvents is approximately 1 and 5 mg/ml, respectively.

Elacridar is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, elacridar should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Elacridar has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Elacridar is a dual inhibitor of P-glycoprotein (MRP-1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). It maximally inhibits P-glycoprotein in isolated human peripheral blood leukocytes at 200 nM.¹ Elacridar blocks the activity of P-glycoprotein at the blood-brain barrier, altering the pharmacokinetics of certain drugs in the brain.² This compound is effective against both human BCRP and the mouse homolog, Bcrp1.^{3,4}

References

1. Witherspoon, S.M., Emerson, D.L., Kerr, B.M., *et al.* Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918. *Clin. Cancer Res.* **2(1)**, 7-12 (1996).
2. Letrent, S.P., Pollack, G.M., Brouwer, K.R., *et al.* Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. *Drug Metab. Dispos.* **27(7)**, 827-834 (1999).
3. de Bruin, M., Miyake, K., Litman, T., *et al.* Reversal of resistance by GF120918 in cell lines expressing the ABC halftransporter, MXR. *Cancer Lett.* **146(2)**, 117-126 (1999).
4. Jonker, J.W., Smit, J.W., Brinkhuis, R.F., *et al.* Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. *J. Natl. Cancer Inst.* **92(20)**, 1651-1656 (2000).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/01/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM